Cipla’s stock rose by 2.5 percent on March 11, reaching a new all-time high of Rs 1,519 per share, continuing its upward trend. In 2024, the pharmaceutical company’s shares have increased by over 20 percent, while the Nifty 50, the domestic benchmark index, has risen by only 3 percent.
According to Nuvama Institutional Equities, a local brokerage firm, Cipla is currently shifting its focus from being solely a pharmaceutical company to becoming a more comprehensive health company.
The company is increasingly involved with startup ecosystems, investing in various areas such as oncology, obesity, mental health, wellness, and genomics. Nuvama mentioned that Cipla sees significant growth opportunities and is expanding beyond traditional medication by exploring different aspects like nutrition, clinics, and digital solutions. This strategic shift is expected to boost its consumer health business.
What are your thoughts? Anyone who has invested?